scispace - formally typeset
J

John de Groot

Researcher at University of Texas MD Anderson Cancer Center

Publications -  262
Citations -  16696

John de Groot is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Glioma & Bevacizumab. The author has an hindex of 47, co-authored 230 publications receiving 12133 citations. Previous affiliations of John de Groot include University of California, San Francisco & University of Texas Health Science Center at Houston.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

Sattva S. Neelapu, +18 more
- 01 Jan 2018 - 
TL;DR: The multidisciplinary approach adopted at institutions is described, and recommendations for monitoring, grading, and managing the acute toxicities that can occur in patients treated with CAR-T-cell therapy are provided.
Journal ArticleDOI

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Timothy F. Cloughesy, +29 more
- 11 Feb 2019 - 
TL;DR: It is suggested that the neoadjuvant administration of PD-1 blockade enhances both the local and systemic antitumor immune response and may represent a more efficacious approach to the treatment of this uniformly lethal brain tumor.
Journal ArticleDOI

An inhibitor of oxidative phosphorylation exploits cancer vulnerability.

Jennifer R. Molina, +66 more
- 11 Jun 2018 - 
TL;DR: Treatment with IACS-010759 robustly inhibited proliferation and induced apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS, likely owing to a combination of energy depletion and reduced aspartate production that leads to impaired nucleotide biosynthesis.
Journal ArticleDOI

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.

John de Groot, +6 more
- 01 Mar 2010 - 
TL;DR: A highly angiogenic, noninvasive orthotopic U87 xenograft tumor was forced to become infiltrative by treating the mice with bevacizumab, which mimicked many of the histopathologic findings from the human cases and will augment the discovery of alternative or additive therapies to prevent this type of tumor recurrence in clinical practice.